Bills Digest No. 13, 2022–23
PDF version [383KB]
Rebecca Storen
Social Policy Section
16
September 2022
Key points
- The Bill proposes to reduce the Pharmaceutical Benefits Scheme (PBS) general co-payment from its current amount of $42.50 to $30.00 (subject to annual indexation) and enable pharmacies to apply an optional discount to the price of some PBS medicines.
- These amendments implement the Australian Labor Party’s election commitment to decrease the general co-payment to $30.00 from 1 January 2023.
- Patients generally pay a co-payment towards the cost of each PBS medicine, with a lower co-payment amount for concession card holders. Once patients have spent over a certain amount on PBS medicines they can qualify for the PBS Safety Net, under which general patients will then pay a lower amount for medicines and concession card holders receive medicines for free for the remainder of the calendar year.
- The amendments proposed in the Bill will primarily benefit people who do not purchase a substantial amount of PBS listed medicines each year and who do not qualify for concession cards.
- The Bill will not modify the PBS Safety Net thresholds. For people with high medicine needs who would expect to reach the Safety Net threshold each year, the reduced general co-payment amount may have limited impact.
- It will also not change the concessional co-payment amount which will increase on 1 January 2023 subject to indexation while the general co-payment will be reduced by $12.50 and will not increase until 1 January 2024.
- As with the existing optional discount, pharmacies have the choice whether to provide the additional discount to general co-payments for eligible medicines (concessional co-payments will be ineligible). Pharmacists will not be reimbursed by the Commonwealth for providing the discount.
|
Contents
Purpose of
the Bill
Background
Committee
consideration
Position of
major interest groups
Financial
implications
Statement of
Compatibility with Human Rights
Key issues
and provisions
Date introduced: 7
September 2022
House: House of
Representatives
Portfolio: Health
and Aged Care
Commencement: 1
January 2023
Links: The links to the Bill,
its Explanatory Memorandum and second reading speech can be found on the
Bill’s home page, or through the Australian
Parliament website.
When Bills have been passed and have received Royal Assent,
they become Acts, which can be found at the Federal Register of Legislation
website.
All hyperlinks in this Bills Digest are correct as
at September 2022.
Purpose of
the Bill
The purpose of the National
Health Amendment (General Co-payment) Bill 2022 (the Bill) is to amend the National Health Act
1953 (the Act) to:
- reduce
the Pharmaceutical Benefits Scheme (PBS) general co-payment from its current
amount of $42.50 to $30 (subject to annual indexation)
- enable
pharmacies to apply an optional discount to the dispensed price of some PBS
medicines.
As part of its 2022 election policies, the Government committed
to reduce the PBS co-payment to a maximum of $30 per script from 1 January 2023,
stating that the changes would ‘save Australians more than $190 million a year
in out-of-pocket costs’.[1]
Background
Co-payments and the PBS Safety Net
Overview
The Australian Government subsidises the cost of many
medicines for Australians through the PBS, with patients often contributing to
the cost as well.[2]
Patients pay a co-payment towards the cost of each PBS medicine, with the
Australian Government generally covering the remaining cost (there are
instances where people may pay
more than the co-payment, for example if they choose a particular brand of
medicine over another brand of the same medicine). This keeps otherwise
expensive medicines affordable for people. Patient
co-payments are currently set at $6.80 for concession
card holders and a maximum of $42.50 for those ineligible for a concession
(known as general patients). Under the Closing
the Gap PBS Co-Payment Program, eligible Aboriginal and Torres Strait
Islander people who would normally pay the full co-payment only pay the
concessional rate, and those who would normally pay the concessional rate are
not required to pay the PBS co-payment.[3]
The PBS
Safety Net scheme is intended to protect patients needing a large number of
medicines in one year from excessive out of pocket costs. Individuals and
families who spend an amount equal to their Safety Net threshold on co-payments
in a calendar year receive further prescriptions for that year for free (if
they are concession card holders) or for the concessional co-payment of $6.80
(if they are general patients).[4]
The co-payments and Safety Net thresholds are indexed on 1
January each year in line with the Consumer Price Index (CPI) and are currently
$244.80 for concession card holders and $1,457.10 for general patients.[5]
Medicines are also available through the PBS that are
priced below the general co-payment amount and are referred to as ‘under
co-payment’ prescriptions. These medicines do not attract a Government subsidy
but account for approximately 30% of all prescriptions dispensed in
2020–21.[6]
The Australian Bureau of Statistics (ABS) estimates that in
2020–21, nearly 2 in 3 people have been supplied with at least 1 PBS medicine,
with data showing that the supply of medicines increases with age and that
people with a disability are more likely to be supplied with a medicine than
people with no disability.[7]
In addition, the ABS estimates that 1 in 7 people were supplied a PBS medicine
using the Safety Net subsidy at least once, again noting that the use of the Safety
Net increases with age and that people with disability were three times more
likely to use the safety net as opposed to those without disability.[8]
Patient contribution to PBS
medicines
Most PBS medicines are dispensed under section 85 of the
Act through community pharmacies for people to use at home. Some medicines,
under section 100 of the Act, are supplied through special arrangements where
normal supply is not suitable (for example, IVF medicines available through the
PBS).[9]
In addition, there are allowances for some medicines to be on hand for free
emergency use, this is traditionally known as a Doctor’s Bag (or, as referred
to in the Act, Prescriber’s Bag).
As shown in Table 1 below, the patient contribution for
section 85 and section 100 medicines (excluding under co-payment prescriptions)
was estimated at approximately $1.5 billion in
2020–21, with patient contribution for general non-Safety Net prescriptions estimated
at approximately $568.5 million (this does not take into account the effect of
the $1 PBS patient co-payment discount, discussed in the next section).[10]
It is the people purchasing medicines who do not qualify for concessional arrangements
or have a Safety Net card , shown in grey in Table 1, that will benefit from
the proposed changes being introduced in the Bill.
Table 1 PBS subsidised
prescriptions, government cost, patient contribution and average price
(2020–21)
Section 85 and section 100, including Doctor’s Bag,
excluding under co-payment prescriptions.
Patient Category |
PBS subsidised
prescription |
Government Cost |
Patient contribution* |
Total cost** |
Ave. price+ |
Concessional Non-Safety Net |
144,098,300 |
$7,010,646,005 |
$917,783,821 |
$7,928,429,826 |
$55.02 |
Concessional Safety Net |
50,743,086 |
$1,985,329,594 |
$0 |
$1,985,329,594 |
$39.13 |
Total Concessional |
194,841,386 |
$8,995,975,600 |
$917,783,821 |
$9,913,759,421 |
$50.88 |
General Non-Safety
Net |
15,552,528 |
$4,414,990,093 |
$568,519,553 |
$4,983,509,646 |
$320.43 |
General Safety Net |
2,813,685 |
$147,503,450 |
$17,923,996 |
$165,427,446 |
$58.79 |
Total General |
18,366,213 |
$4,562,493,543 |
$586,443,549 |
$5,148,937,092 |
$280.35 |
Total (excluding Drs
Bag) |
213,207,599 |
$13,558,469,143 |
$1,504,227,370 |
$15,062,696,513 |
$70.65 |
Doctors Bag |
360,456 |
$14,971,053 |
$0 |
$14,971,053 |
$41.53 |
Total (including Drs
Bag) |
213,568,055 |
$13,573,440,196 |
$1,504,227,370 |
$15,077,667,566 |
$70.60 |
*: the patient contribution does not include the effect of the
$1 PBS patient co-payment discount
**: total cost includes cost to the patient and cost to the
Government for PBS subsidised prescriptions
+: Average price is total cost divided by PBS subsidised
prescriptions.
Source: Pharmaceutical Benefits Scheme, Expenditure
Prescriptions Report tables 2020–21, Table 3(b).
In addition, under co-payment contribution from patients
on PBS-subsidised medicines in 2020–21 was estimated at $1.4 billion dollars.[11]
In total, the Australian
Institute of Health and Welfare estimates that people paid $3.2 billion
towards PBS and Repatriation
PBS (RPBS) prescriptions in 2020–21, equating to approximately 19% of the
total expenditure on PBS and RPBS medicines that financial year. The Australian
Government contributed the remaining 81% of total expenditure.
Recent changes to the safety net
In the 2022–23 Budget, the Morrison Government announced
it would decrease the PBS Safety Net thresholds across the forward estimates,
with the concession card holder Safety Net threshold changing to $244.80 and $1,457.10
for the general patient Safety Net threshold. These changes took
effect on 1 July 2022.
It was estimated by the Government that these changes
would benefit approximately 2.4 million people.[12] At the time, this announcement
received mixed responses with some stakeholders expressing criticism that this
measure would not mitigate rising prescription prices.[13]
Optional discount
Since 1 January 2016, pharmacists and dispensing medical
practitioners have been permitted to offer consumers a
discount of up to $1 on each PBS co-payment, as long as they absorb the
cost of the discount. This discount can be offered to both general and
concessional co-payments for each PBS medicine that is supplied, except for
prescriptions subject to early supply rules.
The discount can be offered when the medicine’s Commonwealth price (discussed
below) is equal to or higher than the co-payment amount.
The discount is not mandatory, it
is the choice of the pharmacist or medical practitioner whether they would like
to give a discount, and the Commonwealth does not reimburse them if a discount
is provided.[14]
As the co-payment amount paid by the patient is used to
calculate their Safety Net amount, any discount offered by the pharmacist or
medical practitioner will mean the patient will have to have more prescriptions
that incur a general co-payment to reach the Safety Net threshold amount (but
will mean they pay less for that particular script).
In 2020–21, 25% of subscriptions dispensed by community
pharmacies (excluding under co-payment prescriptions) were discounted (see
Table 2 for details), with the vast majority of discounts being the maximum
discount of $1.
Table 2 PBS and RPBS
prescriptions dispensed by community pharmacies (2020–21)
Section 85 and section 100, excluding doctor’s bag and
under co-payment prescriptions.
|
|
Concessional prescriptions
|
General prescriptions
|
RPBS prescriptions
|
Total
|
Discounted |
Number |
48,452,938 |
5,200,560 |
1,107,722 |
54,761,220 |
Percentage |
25% |
30% |
15% |
25% |
Non-discounted |
Number |
144,074,462 |
11,911,695 |
6,383,171 |
162,369,328 |
Percentage |
75% |
70% |
85% |
75% |
Total |
Number |
192,527,400 |
17,112,255 |
7,490,893 |
217,130,548 |
Percentage |
100% |
100% |
100% |
100% |
Source: Pharmaceutical Benefits Scheme, Expenditure
prescriptions report tables 2020–21, Table 15(a).
The $1 discount was introduced to enhance competition
between pharmacies.[15]
However, there have been reports that it has not led to equitable outcomes for
people, as it is more likely to be applied to some patients (those that hold a
concession card) and in urban areas. These findings have raised questions on
why the co-payment amounts are not reduced so everyone who needs to make a
co-payment can benefit.[16]
In 2018, the Turnbull Government stated it did not support
recommendations to abolish the $1 discount and this discount continues to be
available under the Act.[17]
Commonwealth price
The Commonwealth
price for medicines is the amount remunerated to community pharmacies and
is calculated based on a formula outlined in the Community Pharmacy Agreement
(CPA),[18]
and are given effect to through a Determination made by the Pharmaceutical
Benefits Renumeration Tribunal.[19]
This formula is made up of the ex-manufacturer
price plus other applicable charges for the supply of PBS medicines. The components
that make up the Commonwealth Price are outlined in Table 3.
Table 3 Components of the
Commonwealth Price
Payment
type |
Value of payment |
Wholesale mark-up (for Ready-Prepared Pharmaceutical
Benefits) |
Where the Ex-Manufacturer Price is up to and including
$5.50 |
$0.41 per dispense |
Where the Ex-Manufacturer Price is over $5.50 and up to
and including $720 |
7.52 per cent of the Ex-Manufacturer Price per dispense |
Where the Ex-Manufacturer Price is over $720 |
$54.14 per dispense |
Administration, Handling and Infrastructure Fee |
Tier One AHI Fee |
For a Listed Brand with a Price to Pharmacists for Maximum
Quantity less than $100 |
$4.28 per dispense of Maximum Quantity |
Tier Two AHI Fee |
For a Listed Brand with a Price to Pharmacists for Maximum
Quantity from $100 and up to and including $2,000
|
Tier One AHI Fee plus 5% of the amount by which the Price
to Pharmacists for Maximum Quantity exceeds $100, per dispense of Maximum
Quantity |
Tier Three AHI Fee |
For a Listed Brand with a Price to Pharmacists for Maximum
Quantity over $2,000 |
Tier One AHI Fee and $95 per dispense of Maximum Quantity |
Dispensing fee (for Ready-Prepared Pharmaceutical Benefits) |
$7.74 per dispense
|
Dispensing fee (for Extemporaneously-Prepared
Pharmaceutical Benefits) |
Dispensing fee for Ready-Prepared Pharmaceutical Benefits,
plus $2.04, per dispense |
Dangerous Drug fee |
$4.80 per Dangerous Drug dispensed |
Additional notes for payment types have been removed.
Source: Department of Health, Seventh
Community Pharmacy Agreement, (Canberra: DoH, 2020), Table 2, 9.
Committee
consideration
The Senate Standing Committee for the Selection of Bills
recommended that the Bill not be referred to a committee for inquiry.[20]
Senate Standing Committee for the
Scrutiny of Bills
The Committee had not reported on the Bill at the time of
writing.
Position of
major interest groups
The Pharmacy Guild of Australia, Australian Patients
Association, Chronic Pain Australia and Musculoskeletal Australia have issued a
joint
press release welcoming the introduction of the Bill. According to one
news article, the Pharmacy Guild had sought a $20 reduction of the
co-payment.
Financial
implications
It is estimated that the Bill will have a financial impact
of $696.1 million.[21]
The Government had previously estimated that the cost of reducing the
co-payment to $30.00 would cost $765.3 million over the forward estimates.[22]
Indexation arrangements for the general co-payment will be
in line with the CPI from 1 January 2024.[23]
Statement of Compatibility with Human Rights
As required under Part 3 of the Human Rights
(Parliamentary Scrutiny) Act 2011, the Government has assessed the
Bill’s compatibility with the human rights and freedoms recognised or declared
in the international instruments listed in section 3 of that Act. The
Government considers that the Bill is compatible as it does not raise any human
rights issues.[24]
Parliamentary Joint Committee on
Human Rights
The Committee had not reported on the Bill at the time of
writing.
Key issues
and provisions
Overview of the amendments
To achieve the proposed changes, the Bill will amend Part
VII of the Act which contains the relevant provisions governing the operation
of the PBS.
The Bill will introduce a new general co-payment amount of
$30 (it is currently $42.50) and a new, optional discount for eligible prescriptions.
For people with high medicine needs that would expect to
reach the Safety Net threshold each year, the reduced general co-payment amount
may have limited impact. While their general co-payment will be less for each
script, they will still need to reach the Safety Net threshold amount (which is
not modified by this Bill) before they are eligible for the Safety Net concession
card (which enables them to pay the concessional co-payment amount for the
remainder of the calendar year).
The Bill does not propose changes to the Safety Net
threshold for general patients. However, the Bill, for the purposes of meeting
the Safety Net threshold, will take into account the price paid for
prescriptions eligible for increased discounting (less the actual discount). The
Bill also does not change the Safety Net threshold or co-payment for concession
card holders or enable increased discounting for prescriptions for concession benefit
and card prescriptions.
Key provisions
Subsection 87(2) of the Act specifies the co-payment
amounts that an approved pharmacist or approved medical practitioner may charge
a general or concessional patient. Subsection 87(2) enables a pharmacist or medical
practitioner to charge the person specific amounts depending on their
circumstances, differentiating between:
- concession
card holders
- people
with a PBS Safety Net card (meaning people who have met the Safety Net
threshold for the year)
- general
patients.
Paragraph 87(2)(e) specifies the arrangement for general patients
who have not reached the Safety Net threshold and for concession card holders where
the prescription is for an early supply of a
specified medicine. Currently the provision states that they can be charged
$28.60, less any allowable discounts (defined under subsection 87(2AAAA) to
mean the optional discount of not more than $1). However, the $28.60 was
inserted into the Act in 2004, to apply from 1 January 2005,[25]
and is subject to annual indexation under section 99G of the Act. The actual
amount that a person may be charged under paragraph 87(2)(e) is currently
$42.50.
Item 5 will remove the reference to $28.60 (less
any allowable discount) and will insert 2 new subparagraphs enabling the
pharmacist or medical practitioner to charge either:
- the
general patient charge amount (less any allowable discount) (proposed
subparagraph 87(2)(e)(i)), or
- if
the supply is eligible for increased discounting, then an amount that is less
than the lowest amount chargeable under proposed subparagraph 87(2)(e)(i) but
greater than nil (proposed subparagraph 87(2)(e)(ii)).
Item 7 will insert proposed note 3 at the
end of subsection 87(2), which specifies that the lowest amount chargeable
would be the amount charged if the pharmacist or medical practitioner gave the
maximum allowable discount (which is something they can nominate to do, it is
not mandatory).
Item 1 will insert a definition for general
patient charge amount into subsection 84(1) of the Act which specifies
the amount of $30. It also notes that this amount will be adjusted each year
under section 99G (see below).
In practice, these amendments will mean that the pharmacist
or doctor can charge the patient:
- $30
(minus up to $1), as defined by the general patient charge amount, or
- for
medicines that meet the criteria for increased discounting (discussed below), a
general patient can be charged less than $30 (the general patient charge
amount) but must be charged more than $0, depending on the optional discount the
pharmacist or doctor has chosen to give the person.
Proposed section 87AA will introduce a new
discounting option (referred to as ‘increased discounting’) that pharmacists
and medical practitioners will be able to choose to apply, if the following
requirements are met:
- It
is for a supply under a ‘general benefit prescription’
- defined
in subsection 84(1) as a prescription other than:
- a
concessional benefits prescription
- an
entitlement card prescription or
- a
concession card prescription.
- The
supply of the medicine to the patient is not an early supply of a specified
medicine.
- At
the time of supply, the Commonwealth price for the medicine was greater than
the general patient charge amount and less than or equal to the increased
discounting upper Commonwealth price which is specified as $42.50 (proposed
subparagraph 87(AA)(c)(ii)).[26]
- The general patient charge amount and the increased discounting
upper Commonwealth price will be subject to indexation.
Section 84C of the Act provides for the circumstances
where a person is eligible to be issued with a concession and entitlement card for
the supply of PBS medicines upon reaching the relevant general or concessional
Safety Net threshold. Item 4 inserts proposed subparagraph
84C(4)(c)(ia) to allow prescriptions eligible for increased discounting to
contribute to the patient’s Safety Net threshold where the amount charged to
the patient is less than the general patient charge amount (less any
allowable discount) but greater than nil.
Section 99 of the Act sets out the circumstances where a
pharmacist or a doctor who has supplied a PBS-listed medicine is entitled to reimbursement
from the Commonwealth. Paragraph 99(2)(b) of the Act provides that an approved
pharmacist or doctor is entitled to be paid, by the Commonwealth, the
difference between the Commonwealth price of the item and the co-payment
charged (less any allowable discount).
Item 11 inserts proposed subsection 99(2C) which
provides that when the supply of the medicine to the patient is eligible for
increased discounting, the pharmacist or doctor can be reimbursed the
difference between the Commonwealth price of the item and general patient
charge amount except where the amount charged for the supply is less than
the general patient charge amount but greater than nil (in this case,
the pharmacist or doctor is not entitled to reimbursement from the
Commonwealth).
Item 16 introduces the indexation arrangements for
the general patient charge amount and the increased
discounting upper Commonwealth price, which would result in:
- the
general patient charge amount first being indexed on 1 January
2024 and
- the
increased discounting upper Commonwealth price being indexed from
1 January 2023.
As such, while the general co-payment will be reduced to
$30 on 1 January 2023 under the proposed amendments and remain at that amount
for the calendar year, the concessional co-payment will be subject to
indexation on 1 January 2023 and thus would be anticipated to increase for the
next calendar year.
[1]. Australian
Labor Party (ALP), Cutting
the Cost of Medications, ALP policy document, Election 2022.
[2]. For
further information on the PBS see, Rebecca Storen, Rosalind Hewett and Emma
Vines, The
Pharmaceutical Benefits Scheme: A Quick Guide, Research paper series,
2021–22, (Canberra: Parliamentary Library, 2022), 2.
[3]. Storen
et al, The
Pharmaceutical Benefits Scheme, 2.
[4]. Storen
et al, The
Pharmaceutical Benefits Scheme, 2.
[5]. ‘PBS
Safety Net thresholds’, Services Australia.
[6]. ‘Medicines
in the health system’, Australian Institute of Health and Welfare.
[7]. ‘Pharmaceutical
Benefits Scheme Supplied Medications’, Australian Bureau of Statistics
(ABS).
[8]. ‘PBS
supplied medication’, ABS.
[9]. For
more information, please refer to The
Pharmaceutical Benefits Scheme: A Quick Guide.
[10]. In
2020–21, the general co-payment was $41.30, and the concessional co-payment
was $6.60. The safety net threshold was $1,497.20 for general patients and
$316.80 for concessional patients.
[11]. The
Pharmaceutical Benefits Scheme (PBS), PBS/
RPBS Report on Under Co-Payment Prescriptions 2020–21, Spreadsheet,
(Canberra: Department of Health and Aged Care, 2021).
[12]. Australian
Government, ‘Part
2: Payment Measures’, Budget Measures: Budget Paper No. 2: 2022–23,
105.
[13]. Emma
Vines, ‘Health
Overview’, Budget Review 2022–23, Research paper, 2021–22,
(Canberra: Parliamentary Library, May 2022), 110.
[14]. Paragraph
99(2)(b) of the Act.
[15]. Alex
Grove, ‘National
Health Amendment (Pharmaceutical Benefits) Bill 2015’, Bills Digest,
121, 2014–15, (Canberra: Parliamentary Library, 2015), 5.
[16]. S.
King, W. J. Scott and J. Watson, Review
of Pharmacy Remuneration and Regulation – Final Report, report prepared
for the Department of Health (DoH), (Canberra: DoH, 2017), 35–36.
[17]. DoH,
Australian
Government Response to the Review of Pharmacy Remuneration and Regulation,
(Canberra: DoH, 2018), 8.
[18]. DoH,
Seventh
Community Pharmacy Agreement, (Canberra: DoH, 2020). “Commonwealth
price” is defined in subsection 84(1) of the Act.
[19]. Commonwealth price
(Pharmaceutical benefits supplied by approved pharmacists) Determination 2020.
[20]. Senate
Standing Committee for the Selection of Bills, Report,
4, 2022, 8 September 2022.
[21]. Explanatory
Memorandum, National Health Amendment (General Co-payment) Bill 2022, 2.
[22]. ALP,
Cutting
the Cost of Medications.
[23]. Explanatory
Memorandum, 2.
[24]. The
Statement of Compatibility with Human Rights can be found at pages 3–4 of the
Explanatory Memorandum to the Bill.
[25]. See
item 7 of Schedule 1 to the National Health
Amendment (Pharmaceutical Benefits Budget Measures) Act 2004.
[26]. Item
13 of the Bill amends section 99F of the Act to insert a definition for ‘increased
discounting upper Commonwealth price’, which refers to the amount
specified in proposed paragraph 87(AA)(c)(ii).
For copyright reasons some linked items are only available to members of Parliament.
© Commonwealth of Australia
Creative Commons
With the exception of the Commonwealth Coat of Arms, and to the extent that copyright subsists in a third party, this publication, its logo and front page design are licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Australia licence.
In essence, you are free to copy and communicate this work in its current form for all non-commercial purposes, as long as you attribute the work to the author and abide by the other licence terms. The work cannot be adapted or modified in any way. Content from this publication should be attributed in the following way: Author(s), Title of publication, Series Name and No, Publisher, Date.
To the extent that copyright subsists in third party quotes it remains with the original owner and permission may be required to reuse the material.
Inquiries regarding the licence and any use of the publication are welcome to webmanager@aph.gov.au.
Disclaimer: Bills Digests are prepared to support the work of the Australian Parliament. They are produced under time and resource constraints and aim to be available in time for debate in the Chambers. The views expressed in Bills Digests do not reflect an official position of the Australian Parliamentary Library, nor do they constitute professional legal opinion. Bills Digests reflect the relevant legislation as introduced and do not canvass subsequent amendments or developments. Other sources should be consulted to determine the official status of the Bill.
Any concerns or complaints should be directed to the Parliamentary Librarian. Parliamentary Library staff are available to discuss the contents of publications with Senators and Members and their staff. To access this service, clients may contact the author or the Library‘s Central Enquiry Point for referral.